Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Clinical trial NCT03509246 · UNKNOWN

Trial details

NCT number: NCT03509246
Sponsor: Seoul National University Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Neoplasm Epithelial High Grade Serous Carcinoma

Start date: 2018-05-15
Primary completion: 2022-03-01
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.